Get the Stockscreener App
14.47
1.63%
-0.24
After Hours:
14.47
4 D Molecular Therapeutics Inc stock is traded at $14.47, with a volume of 1.02M.
It is down -1.63% in the last 24 hours and down -7.95% over the past month.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
See More
Previous Close:
$14.71
Open:
$14.775
24h Volume:
1.02M
Relative Volume:
1.09
Market Cap:
$799.38M
Revenue:
$88.24M
Net Income/Loss:
$-160.90M
P/E Ratio:
-5.4313
EPS:
-2.6642
Net Cash Flow:
$-129.35M
1W Performance:
-4.93%
1M Performance:
-7.95%
6M Performance:
+46.46%
1Y Performance:
+71.85%
1-Day Range:
$14.03
$14.82
1-Week Range:
$13.56
$16.23
52-Week Range:
$6.96
$16.93
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
14.47 | 799.38M | 88.24M | -160.90M | -129.35M | -2.6642 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Nov-07-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock By Investing.com - Investing.com Nigeria
Live 4D Molecular Therapeutics, Inc. (FDMT) Technical Analysis - Traders Union
Form 4 4D Molecular Therapeutics Inc For: 22 September By Investing.com - Investing.com Nigeria
Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock - Investing.com India
4D Molecular (FDMT) legal chief exercises options, then sells 1,635 shares - Stock Titan
4D (FDMT) Stock Today: Rallies +5.45%, Resistance at $15.24 2026-09-17Volume Breakout Ideas - careplusvn.com
Insider David Kirn Sells 58,333 Shares of 4D Molecular Therapeutics Inc (FDMT) - GuruFocus
4D molecular therapeutics CEO Kirn sells $811,003 in stock - Investing.com
4D molecular therapeutics CEO Kirn sells $811,003 in stock By Investing.com - Investing.com UK
4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing - marketscreener.com
4D Molecular Therapeutics (FDMT) CEO sells 58K shares under preset plan - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - theglobeandmail.com
FDMT: 4D-150 gene therapy shows strong safety, efficacy, and commercial momentum in retinal diseases - TradingView
4D Molecular Therapeutics at Morgan Stanley conference: gene therapy push By Investing.com - Investing.com UK
Insider at 4D Molecular (NASDAQ: FDMT) plans new stock sale after recent trades - Stock Titan
4D Molecular Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
This Coinbase Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Benzinga
4D Molecular Therapeutics Grants RSUs to Seven New Non-Executive Employees - Quiver Quantitative
Seven new employees get 96,000 stock units from 4DMT - stocktitan.net
4DMT Announces New Employment Inducement Grants - GlobeNewswire
FDMT: Phase III data for 4D-150 in wet AMD and DME expected next year, targeting major treatment shifts - TradingView
FDMT: 4D-150 targets a paradigm shift in wet AMD with major phase III data expected next year - TradingView
Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 By Investing.com - Investing.com Nigeria
Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 - investing.com
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief trades 584 shares at $14 - Stock Titan
4DMT to Participate in Upcoming Investor Conferences - Yahoo Finance
4D Molecular Therapeutics (NASDAQ: FDMT) CEO sells 69K shares in preset plan - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.7%Here's What Happened - MarketBeat
4D Molecular Therapeutics posts corporate presentation highlighting AAV gene therapy pipeline led by 4D-150 for wet AMD, DME - Bitget
4D (FDMT) Watch: Advances 13.86% to $16.76; Boundary Watch: Price Remains Between $15.92 Support and $17.60 Resistance in Latest TradingSMA Signal - vinanet.vn
David Kirn plans $1.16M 4D Molecular (NASDAQ: FDMT) stock sale - Stock Titan
HC Wainwright Has Bullish Forecast for FDMT FY2027 Earnings - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock - Investing.com
146,185 Shares in 4D Molecular Therapeutics, Inc. $FDMT Bought by Perigon Wealth Management LLC - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock By Investing.com - Investing.com Canada
4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month HighTime to Buy? - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily Executes Stock Option Exercises and Sales Under 10b5-1 Plan - Kalkine Media
4D Molecular Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief sells 3,270 shares - Stock Titan
Scott Bizily plans new 4D Molecular (NASDAQ: FDMT) sale after 10b5-1 stock trades - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 10%Time to Buy? - MarketBeat
Persistent Asset Partners Ltd Makes New $1.94 Million Investment in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
H.C. Wainwright reiterates Buy on 4D Molecular stock, $36 target By Investing.com - Investing.com Nigeria
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
4D Molecular Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is 4D Molecular Therapeutics Inc (FDMT) Undervalued After Q2 Ear - GuruFocus
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):